Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report report published on Sunday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

EGRX stock opened at $0.75 on Friday. Eagle Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $6.81. The business has a fifty day moving average price of $0.73 and a 200-day moving average price of $3.17.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Creative Planning bought a new stake in Eagle Pharmaceuticals in the 3rd quarter worth approximately $59,000. Mackenzie Financial Corp purchased a new stake in Eagle Pharmaceuticals during the second quarter valued at $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Eagle Pharmaceuticals in the second quarter worth about $65,000. Fidelis Capital Partners LLC bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at about $71,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at about $76,000. 85.36% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.